![Disclaimer ,[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (19)
Destaque
Destaque (20)
Semelhante a Changing the Medical Research Paradigm
Semelhante a Changing the Medical Research Paradigm (20)
Último
Último (20)
Changing the Medical Research Paradigm
- 1. Changing the Research Paradigm Regina Awe Society for Independence In Research Insert your logo in this area then delete this text box.
- 5. Public Scrutiny Regarding Pharma Industry Pharmaceutical Company Payments to Physicians Published: March 21, 2007 Doctors’ Ties to Drug Makers Are Put on Close View By GARDINER HARRIS and JANET ROBERTS Published: March 21, 2007
- 12. Can Big Pharma Change?
- 22. Time to be Creative in New Solutions
- 23. Changing the Research Paradigm Thank you for attending Regina Awe Society for Independence In Research Independenceinresearch.org Insert your logo in this area then delete this text box.
Notas do Editor
- The Predictive Safety Testing Consortium, a public–private partnership, led by the non-profit Critical Path Institute (C-Path), is facilitating the sharing of information by industry to develop new tools that can be qualified for use in drug development. This effort is taking place under the advisement of FDA and the European Medicines Evaluation Agency (EMEA). In May 2008, FDA and EMEA announced that they had reviewed and accepted seven new biomarkers—laboratory tests on urine that signal kidney injury. These new tests can now be used in laboratory research to predict the safety of experimental drugs, enabling drugs to reach market faster and with greater confidence in their safety.
- The Predictive Safety Testing Consortium, a public–private partnership, led by the non-profit Critical Path Institute (C-Path), is facilitating the sharing of information by industry to develop new tools that can be qualified for use in drug development. This effort is taking place under the advisement of FDA and the European Medicines Evaluation Agency (EMEA). In May 2008, FDA and EMEA announced that they had reviewed and accepted seven new biomarkers—laboratory tests on urine that signal kidney injury. These new tests can now be used in laboratory research to predict the safety of experimental drugs, enabling drugs to reach market faster and with greater confidence in their safety.
- How long will it be allowed to continue before the government play the monopoly card?
- We to change Public awareness and perceptions Feedback from patients- use technology to report outocmes
- To trusted 3 rd parties